Tech Center 1600 • Art Units: 1600 1671 1672 1674 1675
This examiner grants 100% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18350454 | METHODS AND COMPOSITIONS FOR SENSITIZING PRC2 MUTANT TUMORS TO IMMUNE CHECKPOINT BLOCKADE THERAPY | Non-Final OA | Sloan-Kettering Institute for Cancer Research |
| 18278567 | NOVEL BACTERIOPHAGE HAVING ENTEROTOXIGENIC ESCHERICHIA COLI-SPECIFIC BACTERICIDAL EFFECT AND ANTIBACTERIAL COMPOSITION COMPRISING SAME | Non-Final OA | CJ CheilJedang Corporation |
| 18022033 | CORONAVIRUS NANOBODIES AND METHODS FOR THEIR USE AND IDENTIFICATION | Non-Final OA | UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION |
| 18250252 | Methods for Purification of AAV Vectors by Anion Exchange Chromatography | Non-Final OA | Pfizer Inc. |
| 18300588 | Methods Of Treatment Of High Grade Squamous Intraepithelial Lesion (HSIL) | Non-Final OA | Inovio Pharmaceuticals, Inc. |
| 18279581 | MUC16 PROMOTER CONTAINING VIRUS | Non-Final OA | City of Hope |
| 18555130 | INFLUENZA-CORONAVIRUS COMBINATION VACCINES | Non-Final OA | ModernaTX, Inc. |
| 18555087 | RESPIRATORY VIRUS COMBINATION VACCINES | Non-Final OA | ModernaTX, Inc. |
| 18480841 | METHODS FOR CHARACTERIZING LENTIVIRUSES | Non-Final OA | LONZA HOUSTON, INC. |
| 17638143 | PHARMACEUTICAL COMPOSITION COMPRISING VACCINIA VIRUS AND HYDROXYUREA AS ACTIVE INGREDIENT FOR TREATMENT OF CANCER | Final Rejection | Bionoxx Inc. |
| 18546828 | DETECTION OF PATHOGENS IN PLANTS | Non-Final OA | Purple City Labs, Inc. |
| 18546357 | ADENOVIRUS ENCODING IL-15 | Non-Final OA | Akamis Bio Limited |
| 18269108 | Coronavirus Vaccine | Non-Final OA | The Univesity of Melbourne Grattan Street |
| 18039687 | NOVEL REPLICATION DEFICIENT INFLUENZA A VIRUS INDUCING HIGH LEVELS OF TYPE I INTERFERON | Non-Final OA | BlueSky Immunotherapies GmbH |
| 18044628 | ENGINEERED AAV VECTORS | Non-Final OA | LUDWIG-MAXIMILIANS-UNIVERSITÄT MÜNCHEN |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy